ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The British chemical company Johnson Matthey has landed a 5-year extension of a contract with Sarepta Therapeutics to supply starting materials for the drug firm’s phosphorodiamidate morpholino oligomer (PMO) and peptide PMO drug candidates for the treatment of Duchenne muscular dystrophy. Matthey will produce the PMO materials at facilities in West Deptford, New Jersey, and Devens, Massachusetts.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter